US45258K1097 - Common Stock
IMPEL PHARMACEUTICALS INC
NASDAQ:IMPL (12/15/2023, 8:00:03 PM)
After market: 0.22 -0.02 (-8.75%)0.2411
-0.17 (-41.79%)
Impel Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 160 full-time employees. The company went IPO on 2021-04-23. The firm has designed its Precision Olfactory Delivery (POD) technology to target the vascular-rich upper nasal space, and to provide rapid absorption, consistent drug biodistribution and ease of use for a patient, provider, or caregiver. The Company’s product, Trudhesa, is a liquid formulation of dihydroergotamine (DHE), administered to the upper nasal space using its proprietary POD technology for the acute treatment of migraine headaches with or without aura in adults. The firm is developing its product candidate, INP105, as an upper nasal formulation of olanzapine administered using its POD technology for the treatment of agitation and aggression associated with autism spectrum disorder (ASD).
IMPEL PHARMACEUTICALS INC
201 Elliott Ave. W, Suite 260
Seattle WASHINGTON
P: 12065681466
CEO: Adrian Adams
Employees: 160
Website: https://impelpharma.com/
/PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX: IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop...
It's time to start the week with a breakdown of the biggest pre-market stock movers that are worth watching on Monday morning!
Here you can normally see the latest stock twits on IMPL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: